vs
Side-by-side financial comparison of Gaming & Leisure Properties, Inc. (GLPI) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $420.0M, roughly 1.7× Gaming & Leisure Properties, Inc.). Gaming & Leisure Properties, Inc. runs the higher net margin — 57.0% vs 19.1%, a 37.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 6.3%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 5.0%).
Gaming and Leisure Properties, Inc. is a real estate investment trust (REIT) specializing in casino properties, based in Wyomissing, Pennsylvania. It was formed in November 2013 as a corporate spin-off from Penn National Gaming. The company owns 62 casino properties, all of which are leased to other companies.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
GLPI vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $420.0M | $708.5M |
| Net Profit | $239.4M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 79.4% | 21.6% |
| Net Margin | 57.0% | 19.1% |
| Revenue YoY | 6.3% | 32.0% |
| Net Profit YoY | 40.5% | 15.5% |
| EPS (diluted) | — | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $420.0M | — | ||
| Q4 25 | $407.0M | $708.5M | ||
| Q3 25 | $397.6M | $659.9M | ||
| Q2 25 | $394.9M | $603.3M | ||
| Q1 25 | $395.2M | $558.6M | ||
| Q4 24 | $389.6M | $536.6M | ||
| Q3 24 | $385.3M | $533.3M | ||
| Q2 24 | $380.6M | $528.1M |
| Q1 26 | $239.4M | — | ||
| Q4 25 | $275.4M | $135.1M | ||
| Q3 25 | $241.2M | $111.1M | ||
| Q2 25 | $151.4M | $90.3M | ||
| Q1 25 | $165.2M | $114.6M | ||
| Q4 24 | $223.6M | $117.0M | ||
| Q3 24 | $184.7M | $96.4M | ||
| Q2 24 | $208.3M | $88.4M |
| Q1 26 | 79.4% | — | ||
| Q4 25 | 89.3% | 21.6% | ||
| Q3 25 | 84.8% | 21.5% | ||
| Q2 25 | 61.3% | 20.9% | ||
| Q1 25 | 65.5% | 20.3% | ||
| Q4 24 | 79.1% | 23.4% | ||
| Q3 24 | 70.4% | 21.1% | ||
| Q2 24 | 77.1% | 19.9% |
| Q1 26 | 57.0% | — | ||
| Q4 25 | 67.6% | 19.1% | ||
| Q3 25 | 60.7% | 16.8% | ||
| Q2 25 | 38.4% | 15.0% | ||
| Q1 25 | 41.8% | 20.5% | ||
| Q4 24 | 57.4% | 21.8% | ||
| Q3 24 | 47.9% | 18.1% | ||
| Q2 24 | 54.7% | 16.7% |
| Q1 26 | — | — | ||
| Q4 25 | $0.96 | $4.65 | ||
| Q3 25 | $0.85 | $3.86 | ||
| Q2 25 | $0.54 | $3.10 | ||
| Q1 25 | $0.60 | $3.67 | ||
| Q4 24 | $0.79 | $3.67 | ||
| Q3 24 | $0.67 | $3.01 | ||
| Q2 24 | $0.77 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.5M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.0B | $459.1M |
| Total Assets | $13.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $274.5M | — | ||
| Q4 25 | — | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | $560.8M | $669.4M | ||
| Q3 24 | $560.8M | $656.9M | ||
| Q2 24 | $560.8M | $510.9M |
| Q1 26 | — | — | ||
| Q4 25 | $7.2B | — | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $6.9B | — | ||
| Q1 25 | $6.9B | — | ||
| Q4 24 | $7.7B | — | ||
| Q3 24 | $7.4B | — | ||
| Q2 24 | $6.6B | — |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.6B | $459.1M | ||
| Q3 25 | $4.6B | $293.6M | ||
| Q2 25 | $4.6B | $172.4M | ||
| Q1 25 | $4.2B | $593.6M | ||
| Q4 24 | $4.3B | $825.5M | ||
| Q3 24 | $4.3B | $881.4M | ||
| Q2 24 | $4.1B | $763.6M |
| Q1 26 | $13.8B | — | ||
| Q4 25 | $12.9B | $2.0B | ||
| Q3 25 | $12.8B | $1.8B | ||
| Q2 25 | $12.5B | $1.6B | ||
| Q1 25 | $12.1B | $1.9B | ||
| Q4 24 | $13.1B | $2.1B | ||
| Q3 24 | $12.7B | $2.1B | ||
| Q2 24 | $11.8B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 1.56× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 1.60× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $192.7M | ||
| Q3 25 | $240.3M | $246.2M | ||
| Q2 25 | $293.4M | $148.5M | ||
| Q1 25 | $252.5M | $125.8M | ||
| Q4 24 | $1.1B | $190.7M | ||
| Q3 24 | $270.4M | $149.1M | ||
| Q2 24 | $252.1M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $188.1M | ||
| Q3 25 | $183.0M | $235.5M | ||
| Q2 25 | $272.3M | $142.4M | ||
| Q1 25 | $239.6M | $115.8M | ||
| Q4 24 | $1.1B | $183.0M | ||
| Q3 24 | $261.5M | $138.5M | ||
| Q2 24 | $245.0M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.6% | ||
| Q3 25 | 46.0% | 35.7% | ||
| Q2 25 | 69.0% | 23.6% | ||
| Q1 25 | 60.6% | 20.7% | ||
| Q4 24 | 275.3% | 34.1% | ||
| Q3 24 | 67.9% | 26.0% | ||
| Q2 24 | 64.4% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 14.4% | 1.6% | ||
| Q2 25 | 5.3% | 1.0% | ||
| Q1 25 | 3.3% | 1.8% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 2.3% | 2.0% | ||
| Q2 24 | 1.9% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.10× | 1.43× | ||
| Q3 25 | 1.00× | 2.22× | ||
| Q2 25 | 1.94× | 1.65× | ||
| Q1 25 | 1.53× | 1.10× | ||
| Q4 24 | 4.80× | 1.63× | ||
| Q3 24 | 1.46× | 1.55× | ||
| Q2 24 | 1.21× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLPI
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
